Davita Inc vs Uber Technologies Inc — how do they compare? Davita Inc trades at $230.55 (market cap $14.92B), while Uber Technologies Inc trades at $72.45 (market cap $146.73B). The key difference: Uber Technologies Inc is far larger — about 9.8× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| DVA | UBER | |
|---|---|---|
Market Cap | $14.92B | $146.73B |
Sector | Health | Industrials |
52-Week High | $235.71 | $100.10 |
52-Week Low | $103.87 | $68.61 |
Enterprise Value | $27.47B | $153.05B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Uber (UBER) trades at $72.08, down 3.3% over the past 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $52.02B in 2025 and a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, alongside cost-cutting measures such as HR layoffs and AI spending caps.
The outlook remains positive with an 81.67% analyst buy rating and a consensus price target of $108.92, suggesting significant upside. Key risks include execution challenges in autonomous driving, competitive pressures in key markets like India, and potential regulatory hurdles. Investors should weigh strong fundamentals against evolving industry dynamics.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →